search

Active clinical trials for "COVID-19"

Results 1-10 of 7207

Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Control the Immune Hyperactivation...

Systemic Inflammatory Response Syndrome

The investigators developed a GMP protocol to isolate Treg cells from thymic tissue (thyTreg). The thyTreg cells are being evaluated in a Phase I/II clinical tria l to evaluate the safety and efficacy of the adoptive transfer of autologous thyTreg to prevent rejection in heart transplant children. The preliminary results of the ongoing clinical trial indicate that this therapy is not immunogenic, indicating that allogeneic use of these thyTreg cells would be feasible and safe . The goal of this open-label Phase I/IIa study is to evaluate the safety, tolerability and efficacy of allogeneic thymus derived Tregs (thyTreg) in controlling the Immune Hyperactivation in SARS-CoV-2 infected-patients. These thyTreg cells could inhibit an excessive inflammation, improving life-threatening manifestations, restoring immune balance, and protecting infected tissues.

Recruiting25 enrollment criteria

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)

Covid19

The purpose of this study is to evaluate the effectiveness of repurposed medications (study drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19. Participants will receive either study drug or placebo. Participants will self-report any new or worsening symptoms or medical events experienced while taking study drug or placebo. This study is intended to be all remote with no in person visits, unless the study team feels it is in the best interest of a participant to be seen in person. Prior and current drug arms are listed on clinicaltrials.gov and will be updated with the activation of any new drug arms. Each study arm will also have its own clinicaltrials.gov entry and will include "Pro00107921" in the Unique Protocol ID.

Recruiting11 enrollment criteria

SA55 Injection: a Potential Therapy for the Prevention and Treatment of COVID-19

COVID-19

In this first-in-humans dose escalation study, SA55 will be evaluated for safety, tolerability, and pharmacokinetics. The study is intended to enable future studies of SA55-injection's efficacy in preventing and treating COVID-19.

Recruiting25 enrollment criteria

The Roles of Vitamin D and Microbiome in Children With Post-acute COVID-19 Syndromes (PACS) and...

Post-acute COVID-19 Syndromes

A double-blind study to evaluate the role of human microbiome and vitamin D in the development of long COVID and PACS in children.

Recruiting7 enrollment criteria

Canadian Adaptive Platform Trial of Treatments for COVID-19 in Community Settings

COVID-19

CanTreatCOVID is an open-label, individually randomized, multi-centre, national trial. CanTreatCOVID aims to establish an adaptive platform trial aimed at evaluating the clinical- and cost-effectiveness, practical challenges, and outcomes of therapeutics for SARS-CoV-2 for non-hospitalized patients in Canada. Participants will be randomized to receive usual care (i.e. supportive care and symptom relief) or a study therapeutic, which will be determined by the Canadian COVID-19 Out-Patient Therapeutics Committee. The primary outcomes being evaluated is hospitalization and/or death at 28 days, as well as time to recovery.

Recruiting18 enrollment criteria

A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19

COVID-19

Study of EDP-235 in Non-hospitalized Adults with Mild or Moderate COVID-19.

Recruiting17 enrollment criteria

The COPE Study: Pilot Intervention to Improve Symptom Self-management and Coping in Adults With...

Post COVID-19 ConditionPost-COVID-19 Syndrome

This project is a randomized controlled pilot trial using mixed methods to examine the feasibility, acceptability, and initial effects of a telemedicine group-based intervention designed to improve symptom management and coping in adults with Post-COVID.

Recruiting7 enrollment criteria

Evaluating the Safety and Efficacy of AD17002 Intranasal Spray in Treating Participants With Mild...

COVID-19

AD17002 enhances nasal mucosal innate immunity and has met safety and efficacy endpoints in nasal adjuvant or intranasal immunomodulator studies. The aim of this study is assessing the safety and efficacy of AD17002 in treating patients with mild to moderate COVID-19. All participants will be 1:1:1 divided, randomly, and receive standard of treatment. In addition, participants will be given either placebo, 20 or 40 μg of AD17002 via intranasal route and clinical progresses will be compared.

Recruiting23 enrollment criteria

Efficacy and Safety of Trimodulin (BT588) in Subjects With Moderate or Severe COVID-19

COVID-19 PneumoniaCOVID-19 Acute Respiratory Distress Syndrome4 more

The main objectives of the trial are to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in adult hospitalized subjects with moderate or severe COVID-19. Other objectives are to determine pharmacokinetic (PK) and pharmacodynamic (PD) properties of trimodulin.

Recruiting30 enrollment criteria

Rehabilitation for People With Post COVID-19 Syndrome

Post-COVID-19 Syndrome

Patients who have undergone COVID-19 infection often have long-term sequelae. One of the most prevalent sequelae is pain. The main objective of this research is to investigate the efficacy of chronic pain multidimensional intervention in patients with post-COVID-19 syndrome on health-related quality of life, activity levels, pain knowledge and pain intensity.

Recruiting8 enrollment criteria
12...721

Need Help? Contact our team!


We'll reach out to this number within 24 hrs